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By a human cDNA library screening, we have previously identiﬁed two sequences coding two diﬀerent catalytic subunits of the
proteasome which increase homologous recombination (HR) when overexpressed in the yeast Saccharomyces cerevisiae. Here,
we investigated the eﬀect of proteasome on spontaneous HR and DNA repair in human cells. To determine if the proteasome
has a role in the occurrence of spontaneous HR in human cells, we overexpressed the β2 subunit of the proteasome in HeLa
cells and determined the eﬀect on intrachromosomal HR. Results showed that the overexpression of β2 subunit decreased HR in
human cells without altering the cell proteasome activity and the Rad51p level. Moreover, exposure to MG132 that inhibits the
proteasomeactivity reduced HR inhumancells. Wealsofound thatthe expression ofthe β2 subunitincreases the sensitivityto the
camptothecin that induces DNA double-strand break (DSB). This suggests that the β2 subunit has an active role in HR and DSB
repair but does not alter the intracellular level of the Rad51p.
1.Introduction
Homologous recombination (HR) is essential in mainte-
nancegenomestabilityinallorganisms [1–3].Mostinforma-
tion about the genetic control and mechanisms of HR comes
from studies on the yeast Saccharomyces cerevisiae,w h e r e
deletion of RAD52, RAD51,a n dRAD54 genes profoundly
impairs HR [4, 5]. Speciﬁcally, the understanding of the
HR mechanisms is starting to be elucidated from the recent
advances on the biochemical and structural characterization
of recombinases and other factors that help undergo HR [2].
M o r e o v e r ,a sH Ri sc r u c i a lf o rt h em a i n t e n a n c eo fg e n o m e
integrity, it must be tightly regulated to avoid dangerous and
potentially lethal events. Mutations in the tumor suppressor
genesBRCA1 or BRCA2, which have a regulatory function in
HR, may lead to cancer. Defects in the BLM gene encoding
for a DNA helicase, which regulates the outcome of HR, may
lead to cancer prone disease [2]. In mitotic cells, the primary
role of HR is to repair double-strand breaks (DSBs) that can
be induced by a variety of DNA-damaging agents including
UV and γ-radiation [6–8].
ThefrequencyofmitoticHRcanbemodulatedbyseveral
factors and processes. In yeast, mutations in genes primarily
involved in transcription, DNA replication, or chromatin
remodeling increase HR suggesting that these processes may
have a role in the regulation of HR [9, 10].
he 26Sproteasome consisting ofa 19Sregulatory capand
of a 20S catalytic core, degrades polyubiquitinated proteins
in eukaryotic cells [11]; moreover, recent studies show that
the proteasome may have a nonproteolysis role and suggest
a role of ubiquitination in regulating DNA repair [12–15].
The DSS1 protein, a component of 19S proteasome, is found
to interact with BRCA2 that is known to be involved in HR
[16]. Recently, in S. cerevisiae, it has been demonstrated that
the proteasome is involved in the repair of DNA DSBs [17].
The authors demonstrated that Dss1, which is homologous
to Sem1, is recruited to DSBs. A slow-growth phenotype is
observed in a sem1Δpre9Δ strain particularly in the presence2 Journal of Biomedicine and Biotechnology
of the DNA-damaging agents [17–19]. As Pre9 and Sem1
have a role in the proteolytic activity of the 20S proteasome
[20, 21], the authors suggest that the proteolysis by the
proteasome is involved in DSBs repair [17]. More recently, a
direct involvement of the proteasome in DSB-mediated HR
has been demonstrated also in mammalian cells [14, 22]. In
these studies, the authors used several proteasome inhibitors
to demonstrate that the proteasome inhibition modiﬁes
the usage of DSB repair pathway or that the proteasome-
mediated destruction is necessary for the promotion of HR
at an early step. Although a number of studies reveal several
nonproteolytic functions of proteasome also in mammalian
cells, to date, no evidence directly connects the proteasome
and spontaneous HR.
Previously, in a yeast-based genetic screening, we found
that the overexpression of the catalytic subunit α3( P S M A 3 )
and β2 (PSMB2) of the human proteasome increase HR in
yeast[23].Inthepresentstudy,toshedlightontheroleofthe
proteasome in HR, we overexpressed the catalytic subunit β2
in HeLa cells and determined the eﬀect on the spontaneous
intrachromosomal HR and DNA DSB repair.
2.MaterialandMethods
2.1. Plasmid and Cloning Procedure. The pYES2-PSMB2
was extracted and puriﬁed from yeast as reported in [23].
The PSMB2 cDNA was ampliﬁed by PCR and cloned
in the mammalian expression vector pcDNA6/myc-His A
(Invitrogen) in the EcoRI and XbaI site. The primers used
for the PCR cloning are available upon request. The PCR
conditions were 35 cycles: 94◦C1 m i n ,5 4 ◦C4 5 s e c ,a n d
72◦C 2min, followed by 10min of ﬁnal extension at 72◦C.
The correct frame and orientation of cDNA was veriﬁed by
sequence analysis (BMR Service, Padova, Italy).
2.2. Human Cells Line, MG132 Treatment, and Transfection.
HeLaG1cellline(kindlyprovidedfromMargheritaBignami)
was routinely maintained in DMEM supplemented with
10% fetal bovine serum. The HeLaG1 cells contain an
intrachromosomal recombination substrate consisting of
two hygromycin resistance (hygR) alleles inactivated by the
insertion of 10bp in two diﬀerent sites. One hygR allele inac-
tivated in the PvuI site, whereas the other one is inactivated
in the SacII site. An intrachromosomal recombination event
leads to reversion to HYGR phenotype by gene conversion
or reciprocal exchange [24]. The eﬀect of the proteasome
inhibitoron HR was determined as follows: cells were seeded
(2 × 105 cells per well) in 6-well plate and, after 24 hours,
were incubated for 5 hours with 0.3% DMSO as control
or with 3μM, 10μM, and 30μM MG132 (Calbiochem, San
Diego). Next, cells were trypsinized, counted, and seeded
at the density of 2 × 105 to score for recombinants or 2 ×
102 to measure the vital cells. After 24 hours, hygromycin
(200μg/mL) was added to the plates. Selective medium
was changed twice and, after 10 days, cells were stained
with crystal violet and HYGR clones were counted. Cell
viability was measured by counting colonies formed in
p60 dishes grown after 5-6 days in nonselective medium.
The frequency of HR was calculated by dividing the total
number of HYGR colonies by the number of viable cells.
Moreover, HeLaG1 treated with DMSO or with 30μM
MG132 were used to perform a Western blotting analysis to
check Rad51p expression level as described in the following.
The pcDNA6/myc-His and pcDNA6/myc-His-PSMB2 were
transfected in the HeLaG1 cells using the Lipofectamine
2000 following the manufacturer’s instructions. Blasticidin
(10μg/mL) was added after 24 hours, and HYGR clones were
isolatedandexpanded.Expandedclonalpopulationwasused
to study the eﬀect of the expression of the β2 subunit on HR,
as described above.
2.3.TotalProteinExtractionfromHeLaCells andImmunoblot.
Total protein extract from HeLaG1 was prepared according
to the standard procedure. 2-3 × 106 cells were trypsinized
as described and resuspended in 0.4ml of lysis buﬀer
(20mM TrisHCl pH 8, 20mM NaCl, 1% NP-40, 10%
glycerol, 10mM EDTA) containing the protease inhibitor
mixture 1X (Sigma). Cells were incubated for 1 hour on
ice. Then, the suspension was centrifuged at 10,000rpm at
4◦C for 10 minutes. The supernatant was collected in a
new tube, and the protein concentration was determined
using the Bradford assay (BioRad) following the procedure
recommended by the company. 30μg of total protein extract
waselectrophoresedona10%acrylamide gelandtransferred
on a nitrocellulose membrane. To verify the over-expression
of the β2, we performed a Western blotting analysis using
an anti-myc antibody and anti-PSMB2 antibody (Santa Cruz
Biotechnology, Inc.). Antimouse horseradish peroxidase-
linkedantibody (Amersham Biosciences,Piscataway, NJ)was
used as a secondary antibody. The protein level was detected
using the ECL chemiluminescence solution (BioRad), and
the signals were developed on photographic ﬁlms (Sigma).
The level of α-tubulin was determined as loading control.
2.4. Proteasome Activity Assay. The proteasome activity was
determined in cells expressing the β2 proteasome subunit
by using the Proteasome-Glo Trypsin-Like Cell-Based Assay
(Promega, USA) that allows to measure the total activity in
living cells. This assay, based on the luminogenic proteasome
substrate Z-leucine-arginine-arginine-aminoluciferin, was
carried out in 5,000–10,000 cultured cells according to the
standard protocol recommended by the manufacturer. We
also determined the proteasome activity in the cells after
exposure to the proteasome inhibitor MG132. Cell were
treated with MG132 as described before and seeded at the
concentration of 7,500 cells per well. The total proteasome
activity produces luminescence that is determined as relative
light units (RLUs) using a GloMax-Multi Detection System:
Luminometer (Promega, USA).
2.5. Camptothecin Survival Assay. Camptothecin (CPT) was
dissolved in dimethyl sulfoxide at 290μMa n du s e da t
diﬀerent ﬁnal concentrations. Cells stably expressing the β2
proteasome subunit or containing the empty vector were
seeded at 3 × 102, grown for 24 hours, and then treated for 1
hourwith CPT 10μM, 20μM, 40μM, and 80μM. Thereafter,Journal of Biomedicine and Biotechnology 3
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Figure 1: The proteasome inhibitor MG132 decreases HR in HeLa
cells. (a) HR substrate in HeLaG1 cells. HeLaG1 cells contain
an intrachromosomal recombination substrate consisting of two
hygromycin resistance (hygR) alleles inactivated by the insertion of
10bp and separated by the NeoR that confers resistance to G418.
One hygR allele is inactivated at the PvuI site, whereas the other one
isinactivated attheSacII site.Anintrachromosomalrecombination
event leads to the reversion to hygromycin resistance phenotype
(HYGR) by gene conversion or reciprocal exchange. (b) MG132
reduces HR in HeLa cells. Cells were seeded in a 6-well plate
at the concentration of 2 × 105 per well. After 24h cells were
incubated for 5 hours with 0.3% DMSO as control or with 3μM,
10μM, and 30μM MG132. Next, cells were trypsinized, counted,
and seeded as described in Material and Methods. After 24 hours,
hygromycin (200μg/mL) was added. After 10 days, when the clones
were visible, plates were stainedwithcrystalviolet andhygromycin-
resistant clones were counted. The frequency of HR was calculated
by dividing the total number of HYGR colonies by the number
of viable cells. Data are reported as mean of ﬁve independent
experiments ± standard deviation. Results are statistically analyzed
using Student’s t-test. ∗P<. 05.
cells were washed with PBS and grown in the standard
medium for 7 days. Then, clones were stained with crystal
violet and counted. The survival percentage was calculated
as ratio between the number of clones formed after the CPT
treatment and the negative control.
2.6. Data Comparison and Statistical Analysis. Results were
statistically analyzed using Student’s t-test.
3.Results
We previously reported that the expression of the catalytic
subunit β2 (PSMB2) of the human proteasome increases
HR in yeast [23]. We also found that this eﬀect was fully
abolished in the recombination defective rad52Δ mutant
indicating that the human proteasome subunits interact
functionally with the yeast recombination machinery [23].
Moreover, in spite of the recent ﬁndings about the role of
proteasome in HR and DNADSB repair [14, 25], we decided
to further study the eﬀect of the expression of β2 subunit on
HR in human cells.
3.1. MG132, a Proteasome Inhibitor, Decreases HR in Human
Cells. To examine the role of proteasome on HR, we
used the HeLaG1 cells that contain an intrachromosomal
recombination substrate to score for the recombination
events between two defective HygR alleles (Figure 1(a))[ 24].
As an intrachromosomal HR event (either a gene conversion
or a reciprocal exchange event) leads to the restoration of
defective hygR to the wild type, the frequency of recom-
bination is determined as number of hygromycin resistant
clones per 10−4 vital cells. We used this intrachromosomal
recombination system because we have recently found that
these events are stimulated by the over-expression or the
intranuclear permeation of the Saccharomyces cerevisiae
RAD52 that is involved in HR [16, 26]. First, we determined
whether the inhibition of proteasome aﬀects spontaneous
HR in HeLaG1. Therefore, we treated the HeLaG1 cells with
MG132, a proteasome inhibitor, and determined the eﬀect
on HR. As shown in the Figure 1(b),t h ee x p o s u r et o1 0μM
and 30μM MG132 for 5 hours signiﬁcantly reduced (3-4-
and 5-fold) the intrachromosomal recombination frequency.
The results conﬁrmed an involvement of proteasome on
intrachromosomal HR pathway in human cells [25].
3.2. The Overexpression of the β2 Subunit Decreases Intrachro-
mosomal HR. To check if proteasomes were able to aﬀect
the spontaneous HR in human cells, we created a novel
HeLaG1-derived clonal population stably expressing the β2
subunit of the proteasome. We ﬁrst checked the level of
the protein by Western blot. In Figures 2(a) and 2(b),w e
show that the myc-tagged β2 subunit of the proteasome
was over-expressed either 24 hours after the transfection or
in the stably transfected clone-derived cell population. To
make sure that the level of the β2 subunit of the proteasome
was indeed higher in the clonal population derived from
the pcDNA6/PSMB2 stably transfected HeLaG1 cells than
in the control, we carried out Western blot experiments
using an anti-PSMB2 antibody. Results clearly show that the
proteasome subunit is over-expressed in the HeLaG1 cells
(Figure 2(c)).
We, then, determined the eﬀect of the β2 subunit over-
expression on the spontaneous intrachromosomal HR; as
reported in Figure 3, the frequency of intrachromosomal
recombination was signiﬁcantly reduced (2-3-fold) in the
cells overexpressing the proteasome subunit as compared to4 Journal of Biomedicine and Biotechnology
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Figure 2: The over-expression of the β2 subunit of proteasome decreases HR. To determine if the β2 subunit was over-expressed in HeLaG1
cells, ﬁrst we carried out Western blot analysis of total protein extracts 24 hours after transfection (a) and in the stably clonal population
transfected with the β2 plasmid (b) using the anti-myc as primary antibody to detect the myc-tagged β2 subunit. The endogenous myc is
indicated in (a) and (b) and is used as loading control. In (c), we carried out Western blot using the anti-PSMB2 (β2 subunit) as primary
antibody. 30μg of total protein extract was loaded as follows: lane 1, total protein extract from cells transfected with the plasmid expressing
the β2 subunit; lane 2, total protein extract from cells transfected with the plasmid pcDNA6myc. IntrachromosomalHR was determined 24
hours after the transfection of the HeLa G1 with the plasmid expressing the β2 subunit or with the empty pcDNA6myc (d); recombination
was also measured in the cell population derived from HeLaG1 stably transfected with the plasmid expressing the β2 subunit or with the
empty pcDNA6myc (e). The frequency of HR was calculated by dividing the total number of HYGR colonies by the number of viable cells.
Data are reported as mean of ﬁve independent experiments ± standard deviation. Results are statistically analyzed using Student t-test.
∗P<. 005.
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Figure 3: The over-expression of the β2 subunit of proteasome did not alter the level of Rad51p. We determined the level of Rad51p after
treatment with 30μM MG132. (a) 30μg of total protein extract was loaded as follows: line1: negative control. line 2: extract by cells treated
with MG132. We also determined the eﬀect of the β2 subunit over-expression on Rad51p level. (b) 30μg of total protein extract was loaded
as follows:lane 1: total protein extract by control cells; lane 2: extract by cells overexpressing the proteasome subunit. α tubulin was detected
as loading control.
the negative control. This results again conﬁrm a role of the
proteasome on HR in human cells.
3.3. The Overexpression of the β2 Subunit Does Not Aﬀect the
Cell Protease Activity and the Level of Rad51p. Our results
indicate that the treatment with the proteasome inhibitor
MG132 and the over-expression of β2 catalytic subunit of
the proteasome gave a reduction of HR in HeLaG1 cells.
To further investigate the role of the proteasome in HR,
we determined the level of the total protease activity in the
cells after MG132 treatment and in the HeLaG1 expressing
the β2 catalytic subunit of the proteasome. We detected
the protease activity in a number of living cells ranging
from 5,000 to 10,000 that were cultured in a 96-well plate.Journal of Biomedicine and Biotechnology 5
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Figure 4: The over-expression of the β2 subunit of proteasome
increases the sensitivity to camptothecin. Cells expressing the β2
subunitand cells containingthe pcDNA6/myc vector (control cells)
were seeded at the density of 3 × 10
2 per plate. After 24 hours,
cells were treated for one hour with camptothecin at the following
concentrations: 10μM, 20μM, 40μM, and 80μM. After 7 days, the
clones were stained with crystal violet and were counted.
The over-expression of the proteasome subunit does not
aﬀect the total protease activity as shown by the results
reported in Table 1.Asexpected, MG132 treatment leadstoa
decreaseintheproteaseactivityascomparedtotheuntreated
control (Table 2). Although MG132 and the proteasome
subunit gave the same eﬀe c to nH R ,w ec a nc o n c l u d et h a t
the mechanisms involved are diﬀerent.
As the Rad51 protein level could aﬀect intrachromoso-
mal recombination [27], we determined the level of Rad51p
in the total protein extract from HeLaG1 treated with 30μM
MG132. As showed in Figure 3(a), MG132 induced a very
weak change, if any, in the Rad51p level. Similarly, in the
HeLaG1 expressing the β2 subunit of the proteasome, the
Rad51p level was basically the same as compared to the
negative control (Figure 3(b)).
3.4. The Expression of the β2 Subunit Increases the Camp-
tothecin Sensitivity. Recently, treatment with proteasome
inhibitors has been reported to enhance the sensitivity of
mammalian cells to DNA damage-inducing agents [28].
Moreover, yeast strains carrying deletion in the genes encod-
ing proteasome subunits have a higher sensitivity to DSB-
inducing agents indicating a role of the proteasome in DSB
repair [17]. Thus, we decided to analyze the sensitivity of
HeLaG1 cellstotreatment with CPT, a DNA-damagingagent
thatinducesDSB[17,29].AsreportedinFigure 4,cellsstably
Table 1: Proteasome activity in cells that over-express the β2
subunit of the proteasome.
Luminescence (RLU) × 104
Number of cells CONTROL β2 expressing cells
5,000 48.4 ± 0.14 6 .4 ±0.1
7,500 71.0 ± 0.26 8 .7 ±0.8
10,000 107.1± 16.79 4 .5 ±2.0
Diﬀerent numbers of cells were seeded in a multi-well plate for 24 hours.
After, the protease activity were determined according to the protocol
recommended by the manufacturer. Luminescence was determined as
relative light units (RLU) × 104 using a plate luminometer.
Results are reported as mean of 3 independent experiments ± standard
error.
Table 2: Eﬀect of MG132 on proteasome activity in HeLaG1.
Luminescence (RLU) × 104
MG 132 CONTROL β2 expressing cells
0 148.6 ±1.5 137.2 ±0.3
10μM4 6 .3 ±0.16 3 .4 ±0.6
30μM5 5 .1 ±0.24 2 .0 ±0.2
A number of 7,500 cells was seeded in a multi-well plate and exposed to
MG132 as described in Material and Methods. The protease activity was
determined as reported in the Table 1. Luminescence was determined as
relative light units (RLU) × 104 using a plate luminometer.
Results are reported as mean of 3 independent experiments ± standard
error.
expressing the β2 proteasome subunit appeared to be more
sensitive to CPT than the control cells. These data indicated
that the expression of β2 subunit may increase the CPT
sensitivity by reducing DSB repair by HR.
4.Discussion
HR is one of the most important mechanisms to repair DNA
D S B si ne u k a r y o t e s[ 3, 30]. The eﬃcient repair of DSB is
crucial to guarantee the genomic integrity of organism. Most
proteins implicated in the DNA DSB repair by HR were
identiﬁed using the yeast Saccharomyces cerevisiae as genetic
model [31]. Previously, we have isolated two cDNAs encod-
ing for the human proteasome subunit α3( P S M A 3 )a n dβ2
(PSMB2),which increase HR when over-expressed in awild-
type yeast, but not in the recombination-deﬁcient rad52Δ
yeast strain [1, 23, 32]. Moreover, recently, a functional link
between HR/DNA-DSB repair and proteasome activity was
reported also in mammalian cells [14, 22, 25].
The proteasome inhibitors have been shown to suppress
DNA DSB-induced HR in mammalian cells by abolishing
t h er e c r u i t m e n to ft h eR A D 5 1r e c o m b i n a s et ot h eD N A
damage site [25]. Here, we showed that the proteasome
inhibitor MG132 reduced spontaneous intrachromosomal
HR in human cells, without any dramatic eﬀect on the intra-
cellularlevelofRad51protein.TheconcentrationsofMG132
that reduced HR indeed inhibited the total cell proteolytic
activity. This conﬁrms that the inhibition of proteasome
impairs HR [25]. Although there is no direct evidence
that spontaneous HR is due to DNA DSBs, several studies6 Journal of Biomedicine and Biotechnology
report that spontaneous DSBs may occur in mammalian
cells [33, 34]. On the other hand, in yeast, spontaneous HR
and DNA damage-induced HR are controlled by the same
genetic pathway suggesting that they are deriving from the
same mechanism [1, 5, 8, 10, 32, 35, 36]. Therefore, we can
hypothesize that spontaneous DNA damage is responsible
for the spontaneous level of HR in human cells and the
proteasome may be involved in the HR repair of the spon-
taneous DSBs. We have also over-expressed the β2 subunit
of the proteasome in the HeLa cells, and we have basically
obtainedthe same eﬀect:thefrequencyofintrachromosomal
HR was reduced. To gain more information about the
possible mechanism by which the proteasome may reduce
HR, we measured the total proteasome activity in cells over-
expressing the β2 subunit; the total proteolytic activity in the
cells over-expressing the β2 subunit was basically the same as
in the control cells. Moreover, the expression of β2 subunit
did not alter the level of Rad51p in mammalian cells. This
mayindicatethatthehigherleveloftheβ2subunitinthecells
did not impair the global proteasome activity. However, this
protein may interact with some unidentiﬁed factors involved
in the control of HR; therefore, spontaneous DNA damage
that initiates HR event could be repaired less eﬃciently in
the β2 over-expressing cells as compared to the control cells,
leading to a reduction but not a suppression of the HR. To
our knowledge, no report has studied speciﬁcally the eﬀect
of the over-expression of a proteasome catalytic subunit on
HR; several studies indeed indicate that the over-expression
of the subunit β5o rβ6 enhances proteasomal activity and
protects cells from oxidant agents [37–40]. Our study also
demonstrated that the over-expression of β2p r o t e a s o m e
increased the sensitivity to CTP, a DNA-damaging agent that
induces DNA DSB [17, 29]. Again, this subunit could aﬀect
the DSB repair by interacting with factors involved in DNA
repair and promoting the degradation. This may lead to a
less eﬃcient DNA DSB processing that determines weak but
signiﬁcant decrease in survival. Therefore, the β2 subunit of
the proteasome impairs DNA DSB repair. In conclusion, our
data suggest that the β2 subunit of human proteasome may
have a role in regulating HR and DNA DSB repair in human
cells.
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